Sara M. Tolaney

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Sara M. Tolaney
Oct 18, 2024, 12:10 | Blog
From One-Size-Fits-All to Personalized Treatment: An article by Marleen Kok et al.
Maryam Lustberg shared on LinkedIn: "From One-Size-Fits-All to Personalized Treatment: Challenges and Potential Solutions. Opportunities…
Oct 12, 2024, 14:35 | Blog
Paolo Tarantino: EBCTCG analysis of breast cancer patients outcomes over two decades
Paolo Tarantino shared on X: "What is the actual impact of breast cancer clinical research…
Sep 29, 2024, 15:48 | Blog
Elisabetta Bonzano: Dual HER2 inhibition, mechanisms of synergy
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X: "Dual HER2 inhibition:…
Sep 23, 2024, 09:00 | Insight
Theodoros Kontoulis: Heterogeneity of residual disease (RD) after NACT in breast cancer
Theodoros Kontoulis shared on LinkedIn: “Most viewed in the last 7 days from JAMA Oncology:…
Sep 14, 2024, 19:28 | Insight
Paolo Tarantino: Are all residual diseases equal?
Paolo Tarantino shared on LinkedIn: “ Patients with residual breast cancer after neoadjuvant treatment harbor…
Sep 2, 2024, 17:34 | Blog
Elisabetta Bonzano: Improved efficacy outcomes in early-stage TNBC neoadjuvant ICI therapy
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X: "Neoadjuvant Immune Checkpoint…
Aug 26, 2024, 21:21 | Insight
Integrative Multi-Omic Profiling of Triple Negative Breast Cancer - Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X: “This new study examines integrative multi-omic…
Aug 18, 2024, 07:29 | Blog,Opinion
Paolo Tarantino: Do all patients with TNBC need 5 neoadjuvant drugs + 1 year of IO?
Paolo Tarantino shared a post on X about recent paper by Marleen Kok et al., titled…
Jul 31, 2024, 17:01 | Insight
Sequential Sacituzumab and Talazoparib for triple-negative breast cancer
Clinical Cancer Research shared a post on X about a recent paper by Aditya Bardia…
Jul 29, 2024, 11:19 | Insight
Rasha Aboelhassan: We can give TDM1 in stage I HER2 positive breast cancer
Rasha Aboelhassan shared a post on LinkedIn about a recent paper by Paolo Tarantino et al., commenting:…
Jul 27, 2024, 22:17 | Insight
Commentary led by Marleen Kok highlights all questions in early TNBC post-KN522
Erika Hamilton shared on X: "This commentary led by Marleen Kok highlights all the pertinent…
Jul 26, 2024, 00:03 | Blog
Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522
Elisa Agostinetto shared on X: "Out in JCO a must-read by Marleen Kok on the…
Jul 25, 2024, 20:48 | Insight
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab in HER2+ Breast Cancer
Dana-Farber’s Breast Oncology Center shared on X: "New in JCO Oncology Practice: Subcutaneous vs Intravenous…
Jul 25, 2024, 08:58 | Insight
Marleen Kok: How do we get from one-size-fits-all to personalized treatment for TNBC
Marleen Kok, Breast Medical Oncologist at the Netherlands Cancer Institute, shared on X: "Today from…
Jul 15, 2024, 04:50 | Insight
Paolo Tarantino: Our article on ADCs is among the top 10 most cited in CA Cancer Journal
Paolo Tarantino, shared a post on LinkedIn about a recent paper titled "Antibody–drug conjugates: Smart…
Apr 29, 2024, 14:18 | Drugs
Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer
Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn: “An important…
All: 16 Posts: 1 - 100
Special Coverage